ESAB heads into the week with a striking disconnect: the stock has added 3% since Monday, yet short sellers have been quietly rebuilding positions at their fastest pace in months.
The most striking data point on the tape is the short interest surge, which has climbed 44% over the past month to reach 3.96% of the free float. That move — from roughly 1.56 million shares short in late March to 2.4 million now — marks a significant repositioning. It accelerated sharply around April 23, when estimated short shares jumped by roughly 330,000 in a single session. The ORTEX short score nudged up to 40.9 this week, consistent across recent sessions but still well within moderate territory. Days to cover is nearly six, meaning a meaningful short-covering event would take time to resolve.
The borrow market tells a looser story. Cost to borrow is cheap at 0.44% — well below stress levels — and has barely moved over the month. Availability, while not published in percentage terms here, corroborates the ease: utilization is running at just 9%, close to its 52-week high of 9.68% but still leaving the vast majority of shares in the lending pool untapped. Options positioning has nudged more cautious — the put/call ratio jumped to 0.85 on Friday from a cluster of readings around 0.65–0.67 mid-week, putting it roughly 1.2 standard deviations above its 20-day mean. That's a notable one-session shift, though still a long way from the defensive extremes seen in late March when the PCR briefly pushed above 1.09.
The Street's outlook frames this as a valuation story, not a distress story. Analysts are uniformly bullish — every recent change has maintained Buy or Overweight ratings — though targets have been trimmed. JP Morgan cut its target to $135 from $148 in early April, and Stifel moved from $158 to $138 around the same time. DA Davidson, more recently, trimmed to $142 from $146 while holding its Buy. The mean target now sits at $136, implying roughly 35% return potential against a $100.94 close. The bull case centres on ESAB's Eddyfi acquisition expanding its addressable market by $5 billion and strengthening its position as a differentiated end-to-end industrial solutions provider. Bears counter that heavy reliance on equipment sales and automation headwinds threaten margin sustainability. The EV/EBITDA multiple is running at 12.3x — steady, with only modest movement over the past month. The analyst recommendation differential factor scores at the 92nd percentile, flagging an unusually wide gap between current price and where the Street has converged on value.
The ownership picture reinforces the fundamental-buyer base. T. Rowe Price holds nearly a quarter of outstanding shares at 24.1%, and added over 810,000 shares in the latest reporting period. Vanguard, BlackRock, and State Street all added incrementally in the most recent quarter. The largest individual holder, Mitchell Rales, trimmed a modest 9,333 shares — a de minimis move against a 3.6 million share position. Recent insider activity from March was largely equity award-related, with some small associated sell-to-cover transactions. The 90-day insider net is mildly positive at just under $3.2 million, not a signal of conviction in either direction.
ESAB reported Q1 results on May 7, and the stock dipped roughly 0.6% the following day — a muted reaction that sets the tone going forward. With earnings now out of the way and no confirmed next event on the calendar, the focus shifts to whether the short-interest build — the most aggressive in months — sustains or reverses as sentiment settles around that 35% gap to analyst targets. The interplay between continued position-building and the Street's stubborn constructive consensus is the tension worth watching through the rest of May.
See the live data behind this article on ORTEX.
Open ESAB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
